These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

365 related items for PubMed ID: 16417570

  • 1. Modifications of the iron-neuromelanin system in Parkinson's disease.
    Fasano M, Bergamasco B, Lopiano L.
    J Neurochem; 2006 Feb; 96(4):909-16. PubMed ID: 16417570
    [Abstract] [Full Text] [Related]

  • 2. The enigma of neuromelanin in Parkinson's disease substantia nigra.
    Youdim MB, Ben-Shachar D, Riederer P.
    J Neural Transm Suppl; 1994 Feb; 43():113-22. PubMed ID: 7884393
    [Abstract] [Full Text] [Related]

  • 3. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease.
    Sasaki M, Shibata E, Tohyama K, Takahashi J, Otsuka K, Tsuchiya K, Takahashi S, Ehara S, Terayama Y, Sakai A.
    Neuroreport; 2006 Jul 31; 17(11):1215-8. PubMed ID: 16837857
    [Abstract] [Full Text] [Related]

  • 4. Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson's disease.
    Fedorow H, Tribl F, Halliday G, Gerlach M, Riederer P, Double KL.
    Prog Neurobiol; 2005 Feb 31; 75(2):109-24. PubMed ID: 15784302
    [Abstract] [Full Text] [Related]

  • 5. Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease.
    Zecca L, Casella L, Albertini A, Bellei C, Zucca FA, Engelen M, Zadlo A, Szewczyk G, Zareba M, Sarna T.
    J Neurochem; 2008 Aug 31; 106(4):1866-75. PubMed ID: 18624918
    [Abstract] [Full Text] [Related]

  • 6. The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson's disease.
    Biondetti E, Santin MD, Valabrègue R, Mangone G, Gaurav R, Pyatigorskaya N, Hutchison M, Yahia-Cherif L, Villain N, Habert MO, Arnulf I, Leu-Semenescu S, Dodet P, Vila M, Corvol JC, Vidailhet M, Lehéricy S.
    Brain; 2021 Nov 29; 144(10):3114-3125. PubMed ID: 33978742
    [Abstract] [Full Text] [Related]

  • 7. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it.
    Fahn S, Cohen G.
    Ann Neurol; 1992 Dec 29; 32(6):804-12. PubMed ID: 1471873
    [Abstract] [Full Text] [Related]

  • 8. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease.
    Hirsch E, Graybiel AM, Agid YA.
    Nature; 1988 Jul 28; 334(6180):345-8. PubMed ID: 2899295
    [Abstract] [Full Text] [Related]

  • 9. Neuromelanin and Parkinson's disease.
    Marsden CD.
    J Neural Transm Suppl; 1983 Jul 28; 19():121-41. PubMed ID: 6321645
    [Abstract] [Full Text] [Related]

  • 10. Iron as a vulnerability factor in nigrostriatal degeneration in aging and Parkinson's disease.
    Floor E.
    Cell Mol Biol (Noisy-le-grand); 2000 Jun 28; 46(4):709-20. PubMed ID: 10875434
    [Abstract] [Full Text] [Related]

  • 11. Changed distribution pattern of the constitutive rather than the inducible HSP70 chaperone in neuromelanin-containing neurones of the Parkinsonian midbrain.
    Andringa G, Bol JG, Wang X, Boekel A, Bennett MC, Chase TN, Drukarch B.
    Neuropathol Appl Neurobiol; 2006 Apr 28; 32(2):157-69. PubMed ID: 16599944
    [Abstract] [Full Text] [Related]

  • 12. Neuromelanin in Parkinson's Disease: from Fenton Reaction to Calcium Signaling.
    Knörle R.
    Neurotox Res; 2018 Feb 28; 33(2):515-522. PubMed ID: 28879408
    [Abstract] [Full Text] [Related]

  • 13. A critical review of the function of neuromelanin and an attempt to provide a unified theory.
    Nicolaus BJ.
    Med Hypotheses; 2005 Feb 28; 65(4):791-6. PubMed ID: 15949901
    [Abstract] [Full Text] [Related]

  • 14. The relevance of iron in the pathogenesis of Parkinson's disease.
    Sian-Hülsmann J, Mandel S, Youdim MB, Riederer P.
    J Neurochem; 2011 Sep 28; 118(6):939-57. PubMed ID: 21138437
    [Abstract] [Full Text] [Related]

  • 15. Protective and toxic roles of dopamine in Parkinson's disease.
    Segura-Aguilar J, Paris I, Muñoz P, Ferrari E, Zecca L, Zucca FA.
    J Neurochem; 2014 Jun 28; 129(6):898-915. PubMed ID: 24548101
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Neuromelanin-bound ferric iron as an experimental model of dopaminergic neurodegeneration in Parkinson's disease.
    Gerlach M, Riederer P, Double KL.
    Parkinsonism Relat Disord; 2008 Jun 28; 14 Suppl 2():S185-8. PubMed ID: 18585086
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Parkinson's disease-related increase of T2*-weighted hypointensity in substantia nigra pars compacta.
    Langley J, Huddleston DE, Sedlacik J, Boelmans K, Hu XP.
    Mov Disord; 2017 Mar 28; 32(3):441-449. PubMed ID: 28004859
    [Abstract] [Full Text] [Related]

  • 20. Neuronal vulnerability in Parkinson's disease.
    Double KL.
    Parkinsonism Relat Disord; 2012 Jan 28; 18 Suppl 1():S52-4. PubMed ID: 22166454
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.